Christoph Brackmann serves as Chief Financial Officer of NovoCure Ltd., a global oncology company revolutionizing cancer treatment through its innovative Tumor Treating Fields (TTFields) therapy. With more than 25 years of extensive experience in finance across the healthcare, medical technology, and industrial sectors, Brackmann has established himself as a strategic leader adept at navigating complex financial landscapes, driving growth, and optimizing operations in dynamic markets. Prior to joining NovoCure in 2021, Brackmann held the position of CFO at Brainlab AG, a leading medical technology firm, where he spearheaded financial strategy, supported international expansion, and enhanced profitability through rigorous cost management and M&A activities. His earlier career included senior finance roles at Siemens Healthineers and Siemens AG, where he managed global treasury functions, investor relations, and capital-raising initiatives that fueled multimillion-euro investments in healthcare innovations. A German national, Brackmann earned a degree in Business Administration from the University of Mannheim and is a qualified Chartered Accountant. At NovoCure, Brackmann oversees all financial operations, including budgeting, forecasting, compliance, and capital markets activities, playing a pivotal role in strengthening the company's balance sheet amid rapid commercialization of TTFields devices like Optune and NovoTTF-100A. His achievements include securing key financing rounds and implementing robust financial controls that have supported clinical advancements and global market penetration, positioning NovoCure for sustained growth in oncology.